Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pulmatrix, a biotechnology company, has demonstrated the superiority of iSPERSE, the inhaled drug platform, in delivering an effective therapeutic dose of the active ingredients in Advair, salmeterol and fluticasone, as compared to lactose blend Advair.
Subscribe to our email newsletter
In vitro studies on iSPERSE, a cationic salt formulation, have shown delivery of consistent doses, which can have relevance to patients with lower or impaired lung function.
iSPERSE also showed superiority over conventional inhalation drug delivery technologies in dose delivery, dose efficiency and inhalation flow rate independence.
iSPERSE fluticasone and salmeterol combination was matched to commercially available Advair, which revealed that iSPERSE showed three times greater delivery of drug to the lungs over the lactose blend while maintaining consistent particle size over a range of inhalation flow rates.